{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T16:30:47Z","timestamp":1747153847323,"version":"3.40.5"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T00:00:00Z","timestamp":1676851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T00:00:00Z","timestamp":1676851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s11096-022-01532-2","type":"journal-article","created":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T16:59:01Z","timestamp":1677171541000},"page":"566-576","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Economic evaluation of ferric carboxymaltose compared with placebo in iron-deficient patients with heart failure: a systematic review"],"prefix":"10.1007","volume":"45","author":[{"given":"Aziz","family":"Rezapour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aghdas","family":"Souresrafil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9385-2568","authenticated-orcid":false,"given":"Monireh","family":"Shamsaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Barzegar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahsa","family":"Tashakori-Miyanroudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ensiyeh","family":"Ketabchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,20]]},"reference":[{"key":"1532_CR1","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/ehf2.12432","volume":"6","author":"S Bourguignon","year":"2019","unstructured":"Bourguignon S, Faller M, Champs FO, et al. Budget impact of intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency in France. ESC Heart Failure. 2019;6:559\u201369.","journal-title":"ESC Heart Failure."},{"key":"1532_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ccl.2013.09.009","volume":"32","author":"L Liu","year":"2014","unstructured":"Liu L, Eisen HJ. Epidemiology of heart failure and scope of the problem. Cardiol Clin. 2014;32:1\u20138.","journal-title":"Cardiol Clin"},{"key":"1532_CR3","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.2217\/cer-2019-0074","volume":"8","author":"C Rognoni","year":"2019","unstructured":"Rognoni C, Gerzeli S. Ferric carboxymaltose for patients with heart failure and iron deficiency in Italy: cost-effectiveness and budget impact. J Comp Eff Res. 2019;8:1099\u2013110.","journal-title":"J Comp Eff Res."},{"key":"1532_CR4","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/nrcardio.2010.165","volume":"8","author":"AL Bui","year":"2011","unstructured":"Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011;8:30\u201341.","journal-title":"Nat Rev Cardiol."},{"key":"1532_CR5","doi-asserted-by":"crossref","unstructured":"Savarese G, Becher PM, Lund LH, et al. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovascular research. 2023;118(17):3272\u201387.","DOI":"10.1093\/cvr\/cvac013"},{"key":"1532_CR6","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.ijcard.2013.12.028","volume":"171","author":"C Cook","year":"2014","unstructured":"Cook C, Cole G, Asaria P, et al. The annual global economic burden of heart failure. Int J Cardiol. 2014;171:368\u201376.","journal-title":"Int J Cardiol."},{"key":"1532_CR7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.csbj.2016.11.001","volume":"15","author":"EE Tripoliti","year":"2017","unstructured":"Tripoliti EE, Papadopoulos TG, Karanasiou GS, et al. Heart failure: diagnosis, severity estimation and prediction of adverse events through machine learning techniques. Comput Struct Biotechnol J. 2017;15:26\u201347.","journal-title":"Comput Struct Biotechnol J."},{"key":"1532_CR8","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","volume":"361","author":"SD Anker","year":"2009","unstructured":"Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361:2436\u201348.","journal-title":"N Engl J Med."},{"key":"1532_CR9","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1002\/ejhf.2270","volume":"23","author":"P McEwan","year":"2021","unstructured":"McEwan P, Ponikowski P, Davis JA, et al. Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational cost-effectiveness analysis utilising AFFIRM-AHF. Eur J Heart Fail. 2021;23:1687\u201397.","journal-title":"Eur J Heart Fail."},{"key":"1532_CR10","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1093\/eurjhf\/hft099","volume":"15","author":"G Filippatos","year":"2013","unstructured":"Filippatos G, Farmakis D, Colet JC, et al. Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial. Eur J Heart Fail. 2013;15:1267\u201376.","journal-title":"Eur J Heart Fail"},{"key":"1532_CR11","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1161\/CIRCULATIONAHA.117.027497","volume":"136","author":"DJ van Veldhuisen","year":"2017","unstructured":"van Veldhuisen DJ, Ponikowski P, van der Meer P, et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation. 2017;136:1374\u201383.","journal-title":"Circulation"},{"key":"1532_CR12","first-page":"386","volume":"60","author":"GR Bailie","year":"2010","unstructured":"Bailie GR. Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications. Arzneimittel-Forschung. 2010;60:386\u201398.","journal-title":"Arzneimittel-Forschung"},{"key":"1532_CR13","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.rec.2014.10.010","volume":"68","author":"J Comin-Colet","year":"2015","unstructured":"Comin-Colet J, Rubio-Rodriguez D, Rubio-Terres C, et al. A Cost-effectiveness analysis of ferric carboxymaltose in patients with Iron deficiency and chronic heart failure in Spain. Revista espanola de cardiologia (English ed). 2015;68:846\u201351.","journal-title":"Revista espanola de cardiologia (English ed)"},{"key":"1532_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339: b2535.","journal-title":"BMJ"},{"key":"1532_CR15","unstructured":"Souresrafil A, Shamsaie M, Rezapour A, et al. Cost-effectiveness of ferric carboxymaltose in iron-deficient Patients with chronic heart failure: a systematic review protocol. PROSPERO CRD42022342887. 2022; Available from: https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42022342887"},{"key":"1532_CR16","doi-asserted-by":"publisher","first-page":"e067975","DOI":"10.1136\/bmj-2021-067975","volume":"376","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMJ. 2022;376:e067975.","journal-title":"BMJ."},{"key":"1532_CR17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40560-019-0412-2","volume":"8","author":"AM Higgins","year":"2020","unstructured":"Higgins AM, Brooker JE, Mackie M, et al. Health economic evaluations of sepsis interventions in critically ill adult patients: a systematic review. J Intensive Care. 2020;8:5.","journal-title":"J. Intensive Care."},{"key":"1532_CR18","doi-asserted-by":"crossref","unstructured":"Nargesi S, Rezapour A, Souresrafil A, et al. Cost-effectiveness analysis of pulse oximetry screening in the full-term neonates for diagnosis of congenital heart disease: a systematic review. Iran J Pediatr. 2020;30.","DOI":"10.5812\/ijp.105393"},{"key":"1532_CR19","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1332\/174426410X482999","volume":"6","author":"I Shemilt","year":"2010","unstructured":"Shemilt I, James T, Marcello M. A web-based tool for adjusting costs to a specific target currency and price year. Evid Policy. 2010;6:51\u20139.","journal-title":"Evid Policy."},{"key":"1532_CR20","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1093\/eurjhf\/hfs083","volume":"14","author":"FS Gutzwiller","year":"2012","unstructured":"Gutzwiller FS, Schwenkglenks M, Blank PR, et al. Health economic assessment of ferric carboxymaltose in patients with iron deficiency and chronic heart failure based on the FAIR-HF trial: an analysis for the UK. Eur J Heart Fail. 2012;14:782\u201390.","journal-title":"Eur J Heart Fail"},{"key":"1532_CR21","doi-asserted-by":"publisher","first-page":"492","DOI":"10.3111\/13696998.2015.1029491","volume":"18","author":"T Hofmarcher","year":"2015","unstructured":"Hofmarcher T, Borg S. Cost-effectiveness analysis of ferric carboxymaltose in iron-deficient patients with chronic heart failure in Sweden. J Med Econ. 2015;18:492\u2013501.","journal-title":"J Med Econ."},{"key":"1532_CR22","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1080\/14017431.2018.1546894","volume":"52","author":"T Hofmarcher","year":"2018","unstructured":"Hofmarcher T, Cabrales Alin D, Linde C. Cost effectiveness of implementing ESC guidelines for treatment of iron deficiency in heart failure in the Nordic countries. Scand Cardiovasc J SCJ. 2018;52:348\u201355.","journal-title":"Scand Cardiovasc J SCJ."},{"key":"1532_CR23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1478-7547-12-19","volume":"12","author":"EA Lim","year":"2014","unstructured":"Lim EA, Sohn HS, Lee H, et al. Cost-utility of ferric carboxymaltose (Ferinject(R)) for iron-deficiency anemia patients with chronic heart failure in South Korea. Cost Eff Resour Alloc C\/E. 2014;12:19.","journal-title":"Cost Eff Resour Alloc C\/E."},{"key":"1532_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.","journal-title":"Syst Rev."},{"key":"1532_CR25","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s40273-020-00942-2","volume":"38","author":"DD Kim","year":"2020","unstructured":"Kim DD, Silver MC, Kunst N, et al. Perspective and costing in cost-effectiveness analysis, 1974\u20132018. Pharmacoeconomics. 2020;38:1135\u201345.","journal-title":"PharmacoEconomics"},{"key":"1532_CR26","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1016\/j.clinthera.2021.03.012","volume":"43","author":"A Rezapour","year":"2021","unstructured":"Rezapour A, Souresrafil A, Arabloo J. Economic evaluation of new oral anticoagulants in prevention of venous thrombosis following joint replacement surgery: a systematic review. Clin Ther. 2021;43:e139\u201356.","journal-title":"Clin Ther."}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-022-01532-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-022-01532-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-022-01532-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T11:15:41Z","timestamp":1686222941000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-022-01532-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,20]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["1532"],"URL":"https:\/\/doi.org\/10.1007\/s11096-022-01532-2","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"type":"print","value":"2210-7703"},{"type":"electronic","value":"2210-7711"}],"subject":[],"published":{"date-parts":[[2023,2,20]]},"assertion":[{"value":"15 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}